{"id":"drug-gemcitabine-s-1","safety":{"commonSideEffects":[{"rate":"34%","effect":"Neutropenia"},{"rate":"21%","effect":"Anemia"},{"rate":"14%","effect":"Thrombocytopenia"},{"rate":"43%","effect":"Nausea"},{"rate":"31%","effect":"Vomiting"},{"rate":"25%","effect":"Diarrhea"},{"rate":"24%","effect":"Fatigue"},{"rate":"21%","effect":"Mucositis"},{"rate":"17%","effect":"Stomatitis"},{"rate":"15%","effect":"Alopecia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gemcitabine is a nucleoside analog that is metabolized into its active forms, which are then incorporated into DNA, causing chain termination during DNA replication. S-1 is a combination of tegafur (a prodrug of 5-fluorouracil), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (a cytosine deaminase inhibitor), which enhances the antitumor activity of 5-fluorouracil while reducing its gastrointestinal toxicity.","oneSentence":"Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:35:26.859Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pancreatic cancer"},{"name":"Breast cancer"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT06730009","phase":"PHASE1, PHASE2","title":"Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients","status":"RECRUITING","sponsor":"Medigen Biotechnology Corporation","startDate":"2024-10-21","conditions":"Pancreatic Carcinoma Stage II, Cholangiocarcinoma Resectable","enrollment":42},{"nctId":"NCT07262567","phase":"PHASE3","title":"Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Genfleet Therapeutics (Shanghai) Inc.","startDate":"2025-12","conditions":"Metastatic Pancreatic Cancer","enrollment":320},{"nctId":"NCT06571461","phase":"PHASE3","title":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2024-09","conditions":"Pancreatic Cancer","enrollment":408},{"nctId":"NCT06422156","phase":"PHASE2","title":"SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2024-06-01","conditions":"Advanced Pancreatic Cancer","enrollment":73},{"nctId":"NCT03777462","phase":"PHASE2","title":"Borderline Resectable Pancreatic Cancer Neoadjuvant Chemoradiotherapy Clinicaltrial-1","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2019-04-01","conditions":"Pancreatic Cancer","enrollment":150},{"nctId":"NCT04373928","phase":"NA","title":"Personalized Precision Diagnosis and Treatment of Pancreatic Cancer","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2017-11-10","conditions":"Pancreatic Cancer","enrollment":100},{"nctId":"NCT05028439","phase":"NA","title":"RFA Combined With Chemotherapy for Unresectable Cholangiocarcinoma","status":"COMPLETED","sponsor":"First People's Hospital of Hangzhou","startDate":"2020-01-01","conditions":"Cholangiocarcinoma","enrollment":70},{"nctId":"NCT04319471","phase":"PHASE2","title":"Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2020-06-01","conditions":"Nasopharyngeal Carcinoma","enrollment":70},{"nctId":"NCT04101929","phase":"PHASE2","title":"Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-10-01","conditions":"Metastatic Pancreatic Cancer","enrollment":126},{"nctId":"NCT01430052","phase":"PHASE2","title":"Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Osaka Medical Center for Cancer and Cardiovascular Diseases","startDate":"2009-04","conditions":"Pancreatic Cancer","enrollment":110},{"nctId":"NCT02734680","phase":"NA","title":"IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2016-02","conditions":"Pancreatic Cancer","enrollment":70},{"nctId":"NCT00602745","phase":"PHASE3","title":"S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen","status":"TERMINATED","sponsor":"Sanofi","startDate":"2008-02","conditions":"Pancreatic Neoplasm, Neoplasm Metastasis","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["gemzer","TS-1"],"phase":"phase_2","status":"active","brandName":"Drug: gemcitabine, S-1","genericName":"Drug: gemcitabine, S-1","companyName":"Osaka Medical Center for Cancer and Cardiovascular Diseases","companyId":"osaka-medical-center-for-cancer-and-cardiovascular-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha Used for Pancreatic cancer, Breast cancer, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}